bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
although d-rvd with doublet maintenance may not be the new soc yet ( this needs a phase 3 trial to confirm) this is an important discussion ndmm patients should be having with their treating doctor- should i consider a quad-why? why not? #mmsm #ims2022 #myeloma 
Retired Teacher- Dx with Myeloma 2008- Patient Research Advocate-Curriculum Director @HealthTreeU- @ASH_Hematology & @TheEBMT Speaker-IRB Member, #MMSM